To hear about similar clinical trials, please enter your email below
Trial Title:
Precision Cancer Therapy in Rare Cancers
NCT ID:
NCT06119789
Condition:
Rare Malignant Neoplasm
Conditions: Official terms:
Neoplasms
Imatinib Mesylate
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Intervention model description:
simon two stage model
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Imatinib
Description:
imatinib treatment based on molecular alterations
Arm group label:
treatment according to genetic alterations
Summary:
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that
some of these patients have targetable molecular alterations, and some benefit from
targeted drugs. However in many cases these drugs are not approved for the rare cancers.
In this study the aim is to do advanced molecular diagnostics to identify possible
targets for therapy, and to treat accordingly.
Detailed description:
All patients will have the tumour cells diagnosed with a large genepanel, analyzing more
than 500 genes on DNA / RNA level. Patients will be treated based on the molecular
characteristics of the tumor cells.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- ECOG 0-2,
- identified biomarker,
- reasonable biochemistry
Exclusion Criteria:
- ECOG 3-5
- serious other diseases
Gender:
All
Minimum age:
16 Years
Maximum age:
99 Years
Healthy volunteers:
No
Start date:
August 2024
Completion date:
August 2033
Lead sponsor:
Agency:
Oslo University Hospital
Agency class:
Other
Collaborator:
Agency:
Helse Stavanger HF
Agency class:
Other
Collaborator:
Agency:
University Hospital of North Norway
Agency class:
Other
Collaborator:
Agency:
StOlavs Hospital
Agency class:
Other
Collaborator:
Agency:
Nordlandssykehuset HF
Agency class:
Other
Collaborator:
Agency:
Helse Nord-Trøndelag HF
Agency class:
Other
Collaborator:
Agency:
Sorlandet Hospital HF
Agency class:
Other
Collaborator:
Agency:
Møre og Romsdal Hospital Trust
Agency class:
Other
Collaborator:
Agency:
The Hospital of Vestfold
Agency class:
Other
Collaborator:
Agency:
Helse Fonna
Agency class:
Other
Collaborator:
Agency:
Haukeland University Hospital
Agency class:
Other
Collaborator:
Agency:
Sykehuset Ostfold
Agency class:
Other
Collaborator:
Agency:
Helse Forde
Agency class:
Other
Collaborator:
Agency:
Sykehuset Innlandet HF
Agency class:
Other
Source:
Oslo University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06119789
